Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $191.6 million.

  • Ani Pharmaceuticals' Operating Expenses rose 1345.68% to $191.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $754.9 million, marking a year-over-year increase of 3883.35%. This contributed to the annual value of $613.8 million for FY2024, which is 3954.73% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Operating Expenses stood at $191.6 million, which was up 1345.68% from $197.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Operating Expenses' 5-year high stood at $197.5 million during Q2 2025, with a 5-year trough of $51.5 million in Q1 2021.
  • Its 5-year average for Operating Expenses is $116.9 million, with a median of $104.1 million in 2023.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 1065.68% in 2021, then surged by 6254.57% in 2022.
  • Ani Pharmaceuticals' Operating Expenses (Quarter) stood at $84.7 million in 2021, then increased by 9.17% to $92.4 million in 2022, then soared by 35.19% to $124.9 million in 2023, then skyrocketed by 56.05% to $195.0 million in 2024, then fell by 1.73% to $191.6 million in 2025.
  • Its Operating Expenses stands at $191.6 million for Q3 2025, versus $197.5 million for Q2 2025 and $170.9 million for Q1 2025.